Evan Shepherd is a corporate transactional associate in the Houston office of Gibson Dunn where he practices in the firm’s Transactional Department. He focuses his practice on representing public and private companies and investors on a broad range of complex transactions, including tender offers, cross-border transactions, mergers and acquisitions, asset sales, joint ventures, spin-offs, PIPEs, royalty financings and synthetic royalty financings and other strategic transactions. Evan also counsels companies on general corporate and governance matters.
His corporate representations include XOMA Royalty Corporation, Robert Bosch GmbH, Crescent Biopharma, Inc., Jade Biosciences, Inc., RTW Investments, LLC, Tang Capital Partners, The Kraft Heinz Company, NetApp, Inc., General Electric, Amazon.com, Inc., Mondelez International, Inc., Brown Forman Corporation, Viavi Solutions and Ziff Davis, Inc. (formerly J2 Global), among others.
Evan received his Juris Doctorate from the NYU School of Law, where he was President of the Student Bar Association, editor of the NYU Law Review and recipient of the Vanderbilt Medal for outstanding contributions to the NYU School of Law, and his Bachelor of Science degree in Political Science (Law & Public Policy) from the University of Louisville, cum laude. Prior to joining Gibson Dunn, he was an associate with a top international law firm in London, United Kingdom.
Evan is admitted to practice law in the states of New York and Texas.
Publications
Capabilities
- Mergers and Acquisitions
- Capital Markets
- Emerging Companies / Venture Capital
- Private Equity
- Royalty Finance
Credentials
Education:
- New York University - 2017 Juris Doctor
- University of Louisville - 2014 Bachelor of Science
Admissions:
- New York Bar
- Texas Bar
News & Insights
Firm News
Gibson Dunn Advising XOMA Royalty on XenoTherapeutics and Xeno Acquisition’s Purchase of Repare Therapeutics
Firm News
Gibson Dunn Advising Damora Therapeutics on Sale to Galecto and on $285 Million Private Placement by Galecto
Firm News
Gibson Dunn Advises XOMA Royalty on Acquisition of Mural Oncology